Literature DB >> 1352520

Cerebrospinal fluid neuropeptides in mood disorder and dementia.

C M Banki1, L Karmacsi, G Bissette, C B Nemeroff.   

Abstract

Cerebrospinal fluid (CSF) concentrations of immunoreactive corticotropin-releasing hormone (CRH) and somatostatin (SRIF) were measured in female psychiatric inpatients with DSM-III-R diagnoses of major depression, mania, generalized anxiety and somatization disorder. In addition, elderly patients with dementia disorders, with or without concomitant major depression, were also investigated. CSF SRIF was not significantly different among these groups; on the other hand, mean CSF CRH concentrations were significantly higher in major depression and in dementia with depression as compared with neurological controls with no psychiatric disorders. CSF CRH levels in mania, simple dementia, or anxiety or somatization disorder were not significantly different from the controls. Background physical or clinical variables did not account for the differences in CRH concentrations. It is concluded that CSF CRH elevation may be present in some patients with major depression independent of age and an underlying dementia disorder.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352520     DOI: 10.1016/0165-0327(92)90091-j

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  14 in total

1.  Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.

Authors:  J D Bremner; J Licinio; A Darnell; J H Krystal; M J Owens; S M Southwick; C B Nemeroff; D S Charney
Journal:  Am J Psychiatry       Date:  1997-05       Impact factor: 18.112

Review 2.  The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Anne Maria Möller-Leimkühler; Giancarlo Giupponi; Paolo Girardi; Roberto Tatarelli; David Lester
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-20       Impact factor: 5.270

Review 3.  Role of corticotropin releasing factor in anxiety disorders: a translational research perspective.

Authors:  Victoria B Risbrough; Murray B Stein
Journal:  Horm Behav       Date:  2006-07-25       Impact factor: 3.587

4.  Chronic overexpression of corticotropin-releasing factor from the central amygdala produces HPA axis hyperactivity and behavioral anxiety associated with gene-expression changes in the hippocampus and paraventricular nucleus of the hypothalamus.

Authors:  Elizabeth I Flandreau; Kerry J Ressler; Michael J Owens; Charles B Nemeroff
Journal:  Psychoneuroendocrinology       Date:  2011-05-26       Impact factor: 4.905

5.  Reduced activity of hypothalamic corticotropin-releasing hormone neurons in transgenic mice with impaired glucocorticoid receptor function.

Authors:  I Dijkstra; F J Tilders; G Aguilera; A Kiss; C Rabadan-Diehl; N Barden; S Karanth; F Holsboer; J M Reul
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

6.  Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex.

Authors:  Y Lee; M Davis
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

7.  Intracerebroventricular corticotropin-releasing factor increases limbic glucose metabolism and has social context-dependent behavioral effects in nonhuman primates.

Authors:  Elissa M Strome; G H Trevor Wheler; J Dee Higley; D Lynn Loriaux; Stephen J Suomi; Doris J Doudet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-18       Impact factor: 11.205

Review 8.  Sex differences in molecular and cellular substrates of stress.

Authors:  Debra A Bangasser; Rita J Valentino
Journal:  Cell Mol Neurobiol       Date:  2012-04-10       Impact factor: 5.046

Review 9.  The CRF system, stress, depression and anxiety-insights from human genetic studies.

Authors:  E B Binder; C B Nemeroff
Journal:  Mol Psychiatry       Date:  2009-12-15       Impact factor: 15.992

10.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.